Institutional Activity in Novo Nordisk A/S (NYSE:NVO) A Closer Look

3 min read | December 05, 2024 09:35 AM PST | By Team Kalkine Media

Institutional Activity in Novo Nordisk A/S (NYSE:NVO) A Closer Look — Image source: shutterstock

Institutional Investment in Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S, a leading player in the global pharmaceutical sector, has witnessed notable changes in institutional holdings. Quantinno Capital Management LP increased its stake by 9.2% during the third quarter, acquiring an additional 16,995 shares and bringing its total holdings to 201,981 shares. This adjustment reflects ongoing interest in the company within the institutional sector.

Other significant institutional investors also adjusted their positions in NVO. Envestnet Asset Management Inc. increased its position by 1.4%, now holding over 4.25 million shares. Similarly, Raymond James & Associates added 36,223 shares, reaching 3.52 million shares. These changes highlight continued confidence in the company’s operations and growth potential within the pharmaceutical industry.

Broader Institutional Ownership

Several prominent institutions have shown significant activity in Novo Nordisk’s stock. Natixis Advisors LLC expanded its stake by 2.7%, reaching a total of 3.07 million shares in Q3. International Assets Investment Management LLC made a notable increase, adding 1.79 million shares in the same period. DSM Capital Partners LLC demonstrated substantial growth in its holdings during Q2, now owning 1.59 million shares.

Currently, institutional investors hold 11.54% of Novo Nordisk’s outstanding shares, signifying their influence on the company's strategic direction and market perception.

Novo Nordisk’s Financial Profile

Novo Nordisk’s stock opened at $108.96 recently, with a market capitalization of $488.96 billion. The company’s financial indicators include a price-to-earnings ratio of 35.26, a P/E/G ratio of 1.41, and a beta of 0.40, highlighting its stability and growth attributes. Despite fluctuations, with a 12-month range between $94.73 and $148.15, the company remains a significant player in the healthcare sector.

Novo Nordisk maintains a strong financial structure with a quick ratio of 0.75, a current ratio of 0.94, and a manageable debt-to-equity ratio of 0.43, reflecting its ability to meet short-term obligations while maintaining long-term growth potential.

Business Operations

Novo Nordisk operates through two core segments Diabetes and Obesity Care and Rare Disease. The company’s global reach spans Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. Its ongoing focus on research and development underscores its commitment to addressing complex medical challenges.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.